Information on this site is not intended as medical advice and should not be used as a substitute for consulting with a qualified doctor.
The active substance in CellCept, mycophenolate mofetil, is an immunosuppressive medicine. In the body, it is converted into mycophenolic acid, which blocks an enzyme called ‘inosine monophosphate dehydrogenase’. This enzyme is important for the formation of DNA in cells, particularly in the lymphocytes (a type of white blood cell which is involved in the rejection of organ transplants). By preventing the production of new DNA, CellCept reduces the rate at which the lymphocytes multiply. This makes them less effective at recognising and attacking the transplanted organ, lowering the risk of the organ being rejected.1
In Bangladesh CellCept is approved for the following indications.2
CellCept in combination with corticosteroids and either ciclosporin or tacrolimus is indicated for:
prophylaxis of acute organ rejection and treatment of first or refractory organ rejection in patients receiving allogeneic renal transplants
prophylaxis of acute organ rejection in patients receiving allogeneic cardiac transplants. (In the treated population, MMF improved survival in the first year after transplantation).
prophylaxis of acute organ rejection in patients receiving allogeneic hepatic transplants
CellCept is indicated for induction and maintenance therapy of patients with Class III-V lupus nephritis (diagnosed according to International Society of Nephrology/Renal Pathology Society classification).
For more disease and medicine related queries you may discuss with your physician.
In Bangladesh CellCept is available as
Tablets 500 mg
To ensure patient safety and quality, it is strongly recommended to verify that, each medicine comes with the Roche Hologram Sticker, DGDA approved DAR (Drug Administration Registration) Number imprinted on it. Neither Radiant nor Roche Bangladesh takes liability of any other sources of products.
References
CellCept | European Medicines Agency. [Internet; cited 2018, November 12]. Retrieved from
CellCept Product Information BD Ro 106-1443June 2021
This website contains information which is targeted to the people of Bangladesh and could contain product details or information otherwise not accessible or valid in your country. Roche Bangladesh is not responsible for accessing such information that may not be in accordance with legal, regulatory, registration or use processes in your home country. Please note that, information on this site is not intended as medical advice and should not be used as a substitute for consulting with qualified doctor. We are unable to answer questions on individual disease treatment/ management matters. These should be discussed with your physician. We cannot answer product-related questions through this website. Nor this site acts as promotional/ commercial tool for products. It is not permissible to take the contents of this site and use it for commercial purpose, without written consent of Roche Bangladesh.